WO2018222164A2 - Use of an herbal formula containing pumpkin seed oil in bph treatment - Google Patents

Abstract

In the pharmaceutical industry, the present invention is related to the use of an herbal formulation in the form of a soft capsule having antioxidant properties, prepared with pumpkin seed oil particularly rich in terms of essential fatty acids content in the treatment BPH (Benign Prostate Hyperplasia). Said herbal formulation comprises pumpkin seed oil, dl α-tocopherol, dl α-tocopheryl acetate, glycerin, distilled water, and gelatin which provide the integrity of the contents and capsule formation.

Description

USE OF AN HERBAL FORMULA CONTAINING PUMPKIN SEED OIL IN BPH

TREATMENT

TECHNICAL FIELD

The present invention is related to the use of an herbal formulation comprising the pumpkin seed oil (Oleum Cucurbitae semen) in the pharmaceutical industry in the chemical industry.

In particular, the invention is related to the use of an herbal formulation in treatment of BPH (Benign Prostate Hyperpiasia/benign prostatic growth) in the form of a soft capsule with antioxidant feature prepared with pumpkin seed oil which is rich in terms of essential fatty acids.

STATE OF THE ART

Essential fatty acids are the fatty acids that cannot be synthesized within the body and which should be taken from the outside in order to maintain the organism's life. These essential fatty acids should be taken into the organism via nutrients or by certain supplements. Essential fatty acids taken from the outside into the organism, serve as assistants to the treatment of BPH (Benign Prostate Hyperpiasia/benign prostate growth).

In the present art; within the products that are used as assistants to treat BPH (Benign Prostate Hyperpiasia/benign prostatic hyperplasia) synthetic substances or chemicals in certain proportions are present The use of synthetic and chemical substances causes many side effects within the organism and affects many systems of the body badly.

Also, products are in liquid form within most of the current implementations. This situation makes it difficult to carry out controlled dosing. Therefore, required dosage cannot be provided completely and clearly.

One of the related patents in the literature is the application no. CN105981810. The present invention mentions yeasted yoghurt made from the mixture comprising many herbal products as well as pumpkin seed extract, water and high proportion of milk, which regulates blood pressure, activates spleen and kidney, assists in constipation treatment and has anti-aging effect. Application no, CN102908544 which is in the present art refers to a formulation which is good for heart health, which is made by mixing a lot of herbal materials proportionally, such as pumpkin seed, and mentions preparation technique of said formulation by boiling.

As a result, due to the above described drawbacks and the inadequacy of the current solutions, a technical field development of BPH (Benign Prostate Hyperplasia/benign prostate growth) of pumpkin seed oil has become essential. OBJ ECT OF THE INVENTION

The main object of the invention is to provide an herbal formulation containing pumpkin seed oil (Oleum Cucurbitae semen) to help in the treatment of BPH (benign prostatic hyperplasia/benign prostate growth). Pumpkin seed oil inhibits 5- reductase enzyme. It has been reported it inhibits the conversion of testosterone into dihydrotestosterone (DHT) thereby assisting in the treatment of prostate gland related diseases.

Pumpkin seed oil prevents urinary incontinence by loosening the bladder muscles when the bladder is filled with nitric oxide. Due to these dual effects on pelvic muscles and nitric oxide, pumpkin seed oil reduces incontinence. Pumpkin seed oil can also be used as an adjunct to treatment of urinary tract infections, especially cystitis.

Another object of this invention is to ensure that the formed formulation is 100 % natural and herbal content without comprising any chemicals. Even when the pumpkin seed oil used in the formulation is obtained, no heat treatment or chemical treatment is applied. So; the active substances, nutritional values and minerals within the plant, pass directly to the product without getting lost.

Another object of this invention is to provide reducing the side effects that affect human health to a minimum, thanks to the content created without the chemicals. Side effects that affect only the gastrointestinal system such as nausea, vomiting and diarrhea, are observed very rarely with the use of completely natural and herbal products.

Another object of the present invention is to provide ease of use in terms of patient compliance, with the created formulation being in capsule form. Also, thanks to created capsule form, it is advantageous to obtain dosing in said indications. D ETAIL E D DE S C RIPTION O F TH E INV E NTIO N

T he preferred use of an herbal capsule formulation obtained using pumpkin seed oil to achieve the object of this invention is disclosed only for the sake of better understanding of the present invention and without any limiting effect

P umpkin seed oil has been used for centuries as an herbal medical product. P umpkin seed oil shows many different pharmacological effects due to the wide variety of substances within the composition and to the different therapeutic activities of each.

P umpkin seeds; are rich in terms of phytosterols, tocopherols and essential fatty acids (mostly iinoieic and oleic acid) and the active components within the pumpkin seeds are V7- sterols (avenasterol and spinasterol) and ^-sterols (sitosterol, stigmasterol). P umpkin seed oil inhibits 5- reductase enzyme. It has been reported it inhibits the conversion of testosterone into dihydrotestosterone (DHT) thereby assisting in the treatment of prostate gland related diseases.

Many nonclinical and clinical studies have been conducted to investigate the effects of pumpkin seed oil on benign prostatic hyperplasia. In clinical trials, it has been shown that pumpkin seed oil can be used in a clinically safe manner to aid in the treatment of benign prostatic hyperplasia.

P umpkin seed oil has been used for many years as an adjuvant to antihelminthic (schistosomiasis, tapeworm, etc.) treatment In a clinical trial, it has been shown that pumpkin seeds may be helpful for S chistosomiasis, a serious parasitic disease that spreads through snails primarily in Asia and Africa. Also, it has been reported that pumpkin seeds may be helpful in the treatment of tapeworms. C aps ule formulation content:

In the formulation, pumpkin seed oil is used as the active substance and dl -tocopherol, dl -tocophery! acetate, glycerin, purified water and gelatin are used as auxiliary substances, dl -tocopherol and dl -tocophery! acetate are used as protecting agents. In said formulation, dl -tocopherol, dl -tocopheryl acetate are added at ppm level. For gelatin used to provide the integrity of the content, beef gelatin is used. As an alternative to gelatin, other animal- derived and herbal gelatins can be used. As indicated in Table 1 , 42.635% pumpkin seed oil; 0.0030% dl -tocopherol; 0.0213% dl tocopheryi acetate; 10,723% glycerin; 23,312% water; 23,312% gelatin by weight, are used.

Table 1. C ontent of the caps ule and percentages by weight

ule prod uction metho T he manufacturing steps of the capsule formulation are as follows; the pumpkin seed, one of the raw materials, is subjected to sieving. Breaking process is performed if necessary after the sieving process. T he pumpkin seed is sent to the cold press unit after said processes and after the desired size is obtained. The process of oil removal from the raw material is carried out by the cold press method, in said method, 55sQ should not be exceeded. The oil from the cold press unit is kept in mixing and resting tanks prior to filtration. Thus, it is easy to separate the possible particles by mixing and resting processes.

E xtracted oil; after mixing and resting tanks, is fed to the filter unit indoors and at room temperature. In the filter unit; the particles, if any in the oil content are filtered. After the filtration step, dl -tocopherol as a preservative and dl -tocopheryi acetate as a preservative are added to the obtained oil. T hus, the mixture forming the content is obtained.

While these operations are being performed, on the other hand in the gelatin preparation unit, gelatin used to provide capsule integrity is prepared.

Following the formation of the mixture and the preparation of the gelatin, capsules are prepared at the desired dosage by dispensing to the capsule production unit. S aid capsule is soft gelatin capsule. After the capsule is prepared, drying is carried out. Dried capsules are packed.

C aps ule Usage instruction:

T he capsule is rich in terms of essential (basic) fatty acids content. It is used to help treating B P H (Benign P rostate Hyperplasia).

3 Dosage administration frequency and duration: if not otherwise recommended by the doctor; in adults, 1 -3 capsules (960-2880 mg/day dose) are taken orally 3 times a day.

5 Method of administration: Capsules should be swallowed with sufficient water without crushing or chewing in mouth, preferably in full stomach.

Additional Information on S pec ial Populations: δ Kidney/liver failure: T his should not be used in these patient groups as there is no adequate safety study in kidney and liver patients.

S Pediatric population: T he capsule should be used for under the age of 18 in children and adolescents under physician control.

SG eriatric population: There are no studies conducted in the elderly.

C ontraindications

- it should not be used when there is an allergy to the active substance or any component of the capsule,

- During pregnancy and breastfeeding,

- In patients with liver and kidney failure.

S ec ial Warnings and P recautions for Us e Patients using oral anticoagulant drug should not exceed 3 g daily dose of capsules.

E ach capsule contains 0.0805 g glycerin. However, no side effects due to glycerin are expected at this close.

C onsult your doctor or pharmacist if you experience symptoms such as fever, spasm, blood in your urine, painful urination, or urinary retention during your capsule use. it is recommended to continue using the capsule longer than 2 months in consultation with the doctor.

S G eneral R ecommendation: Women with childbearing potential/should not be used because there is no study related to contraception. θ P regnancy period: C linical data on exposure to pumpkin seed oil in pregnancies are not available. S tudies in animals are inadequate with regard to pregnancy and/or embryonal/fetal development and/or postnatal and/or postnatal developmental effects. T he potential risk to people is unknown. There is no adequate information on its use with oral contraceptive drugs. S ince its safety is not shown in pregnancy, it is not recommended to use the capsule during pregnancy. θ Lactation period: S ince its safety in lactation is not shown, it is not recommended to use the capsule in lactation.

U ndes ired Affects

6 G astrointestinal Diseases: C ommon nausea, vomiting, diarrhea. Apart from these, no undesirable effect has been reported to date.

Overdose

No overdose has been reported until today with regard to pumpkin seed oil. P umpkin seed oil, which is used orally, can be well tolerated, without any effect due to overdose. However, if any signs of overdose are present treatment should be symptomatic and supportive. T here is no method to increase a specific antidote and its elimination. Storage Conditions

The shelf life of the product is 2 years. The capsule, content and production methods of which mentioned above, has been licensed by Republic of Turkey Ministry of Health authorities as "Traditional Herbal Medical Product". Said license has the order number 2016/825 dated 21st of November 2016; called ZADE VITAL CUCURMIN 320 mg as a soft capsule. According to the above listed Indications and Traditional Herbal Medicine Product Directive, it is a Traditional Herbal Medicine Product LICENSED by Republic of Turkey Ministry of Health, There are products containing numerous synthetic chemicals licensed for indications specified in the market However, there is no traditional herbal medical product in this area with such an indication licensed by health authorities.

In the majority of current applications; while production in poor hygiene conditions is matter of concern, related formulation is produced under GMP (Good Manufacturing Practices) norms, which the Ministry of Health requests from the pharmaceutical factories.

As known, it is a very difficult operation to provide standardization in herbal products. Within the related formulation;

Sin its seed; pesticide, afiatoxin, heavy metal and active substances analysis, microbiological controls have been conducted.

S In cold press oil; method development, validation and microbiological controls for the analysis of active substances have been conducted.

Sin design; which product?, which indication?, what dose?, what dosage form? to be have been calculated.

Sin the preformuiation; which active substanceAvhich analysis of the auxiliary substance?, which microbiological controls?, which quality control parameters, which stability studies to be done are considered and a system has been developed accordingly. 3 In stability studies; stability studies have been proven to demonstrate conformity to specified specifications during the anticipated shelf life; 24 months study under 25¾3 e 2, 60e5% humidity and 6 months study under 40S3 e 2, 75% e 5 humidity, have been carried out. Validations and data and package specifications, package specifications, interactions, analysis and control methods related to analytical test methods are determined.

Sin preparation of capsule base and internal materials, content determination (oil component analysis), some viscosity and optical appearance control, etc. tests were conducted. δΐη the production procedure; quality control procedures such as qualitative and quantitative content determination, in-process controls such as optical control and content determinations, microbiological analyzes, optical control, etc. have been applied. Also, H P LC analysis of the active ingredient and product sample was made and fatty acid compositions were calculated. Also, the calibration tables of the active substance are prepared.

T he processes described above; are very important details in terms of standardization of herbal products and are detailed in this product. This product has been licensed and approved for pharmacodynamic properties of a Traditional Herbal Medicine product by a health authority such as the Ministry of Health. This product has been approved by a health authority, such as the Ministry of Health, by licensing the KU B (S hort P roduct Information- P rospectus) and KT (Usage Instructions) of a Traditional Herbal Medical product. This product has been approved by a health authority such as the Ministry of Health by standardizing and licensing the use of a T raditional Herbal Medicina l product as a form and use. In this sense, the traditional herbal medical product licensed by the Ministry of Health, dosing of which is stated in writing in compliance with the clinical studies has been officialized by obtaining the approval of health authorities and has been presented to the service of world medicine.

REFERENCES

Abdel-Rahman, M. K. (2006). "Effect of Pumpkin Seed (Cucurbita pepo L.) Diets on Benign Prostatic Hyperplasia (BPH): Chemical and Morphometric Evaluation in Rats." J ournal of World Chemistry 1(1): 33-40.

Ageless. (2014). "Pumpkin seed (squash seed) Cucurbita Pepo." Retrieved 16.04.2014, 2014.

Applequist, W. L, B. Avula, B. T. Schaneberg, Y. H. Wang and I. A. Khan (2006).

"Comparative fatty acid content of seeds of four Cucurbita species grown in a common

(shared) garden. "J ournal of Food Composition and Analysis 19: 606-611.

EFLA÷ (2006). "Pumpkin Seed Special Extract: New in vitro studies on the efficacy and mode of action in incontinence disorders." Frutarom Switzerland Ltd.

Ejike, C. E. and L. U. Ezeanyika (2011). "Inhibition of the experimental induction of benign prostatic hyperplasia: a possible role for fluted pumpkin (Telfairia occidentalis

Hook f.) seeds." Urol Int87(2): 218-224.

EMA (2012). Community herbal monograph on Cucurbita pepo L, semen. European Medicines Agency-Science Medicines Health. E. M. A. C. o. H. M. P. (HMPC). United Kingdom.

Fruhwirth, G. O. and A. Hermetter (2007). "Seeds and oil of the Styrian oil pumpkin: Components and biological activities." Eur.J . Lipid Sci. Technol.109: 1128-1140.

Gossell-Williams, M., A. Davis and N. O'Connor (2006). "Inhibition of testosterone- induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil." J Med Food 9(2): 284-286.

Harvath, S. and Z. Bedo (1988). "Another possibility in treatment of hyperlipidemia with peponen of natural active substance." Mediflora 89: 7-8.

Hata, K. (2005). "Effects of pumpkin seed extract on urinary bladder function in anesthetized rats." Medical Science and Pharmaceutical Science 54(3): 339-345.

Herbalencounter. (2014). "The many uses of Pumpkin Seed (Cucurbita Pepo): from Arthritis to Prostate Health." Retrieved 16.04.2014, 2014.

Ho, M. H., N. N. Bhatia and S. Bhasin (2004). "Anabolic effects of androgens on muscles of female pelvic floor and lower urinary tract" Curr Opin Obstet Gynecol 16(5): 405-409. Hong, H., C. S. Kim and S. Maeng (2009). "Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia." Nutr Res Pract3(4): 323-327.

Loy, J . B. (1990). Hull-less seeded pumpkins: a new edible snackseed crop. Advances in new crops. J . E. Simon. Portland, Timber Pres.: 403-407. I Murkovic, M., V. P iironen, A. M. Lampi, T. Kraushofer and G . S ontag (2004). "C hanges in chemical composition of pumpkin seeds during the roasting process for production of pumpkin seed oil (Part 1 : non-volatile compounds)." Food C hemistry 84: 359-365.

I Paksoy, M. and C . Aydyi (2004). "S ome physical properties of edible squash (C ucurbita pepo L.) seeds." J ournal of Food E ngineering 65: 225-231.

I PP uummppkkiinn SS eeeedd OOiill.. ((22001144)).. ""hhjjttpp:://yywwwwyyyy,,oorrggaann::CC iiooooddeeee oonn //hheerrbbss//ppuummppkkiinnsseeeeddooiill ""

RR eettrriieevveedd 0011..0044..22001144,, 22001144..

I RRyybbaallttoovvsskkiiii,, OO.. VV.. ((11996666)).. ""[[OO nn tthhee ddiissccoovveerryy ooff ccuuccuurrbbiittiinn~~aa ccoommppoonneenntt ooff ppuummppkkiinn sseeeedd wwiitthh aanntthheellmmiinnttiicc aaccttiioonn]].."" MMeedd PPaarraazziittooll ((MMoosskk)) 3355((44)):: 448877--448888..

i SS tteevveennssoonn,, DD.. GG ..,, FF.. JJ .. EE lllleerr,, LL.. WWaanngg,, JJ .. LL.. JJ aannee,, TT.. WWaanngg aanndd GG .. EE .. IInngglleetttt ((22000077)).. ""OOiill aanndd ttooccoopphheerrooll ccoonntteenntt aanndd ccoommppoossiittiioonn ooff ppuummppkkiinn sseeeedd ooiill iinn 1122 ccuullttiivvaarrss.."" JJ AAggrriicc

FFoooodd CC hheemm 5555((1100)):: 44000055--44001133..

I SS ttuuaarrtt,, AA.. GG .. ((22000033)).. PP uummppkkiinn SS eeeeddss..

I SS uupphhaakkaarrnn,, VV.. SS ..,, CC .. YYaarrnnnnoonn aanndd PP .. NNgguunnbboooonnssrrii ((11998877)).. ""TT hhee eeffffeecctt ooff ppuummppkkiinn sseeeeddss oonn ooxxaallccrryyssttaalllluurriiaa aanndd uurriinnaarryy ccoommppoossiittiioonnss ooff cchhiillddrreenn iinn hhyyppeerreennddeemmiicc aarreeaa.."" AAmm JJ CC lliinn NNuuttrr 4455((11 )):: 11 1155--112211..

I SS uupphhiipphhaatt,, VV..,, NN.. MMoorrjjaarrooeenn,, II.. PP uukkbboooonnmmee,, PP .. NNgguunnbboooonnssrrii,, TT.. LLoowwhhnnoooo aanndd SS ..

DDhhaannaammiittttaa ((11999933)).. ""TThhee eeffffeecctt ooff ppuummppkkiinn sseeeeddss ssnnaacckk oonn iinnhhiibbiittoorrss aanndd pprroommootteerrss ooff uurroolliitthhiiaassiiss iinn TThhaaii aaddoolleesscceennttss.. "" JJ MMeedd AAssssoocc TThhaaii 7766((99)):: 448877--449933..

i TTssaaii,, YY .. SS ..,, YY.. CC .. TToonngg,, JJ .. TT.. CC hheenngg,, CC .. HH.. LLeeee,, FF.. SS .. YYaanngg aanndd HH.. YY .. LLeeee ((22000066))..

""PP uummppkkiinn sseeeedd ooiill aanndd pphhyyttoosstteerrooll--FF ccaann bblloocckk tteessttoosstteerroonnee//pprraazzoossiinn--iinndduucceedd pprroossttaattee ggrroowwtthh iinn rraattss.."" UUrrooll IInntt 7777((33)):: 226699--227744..

I YYaannaaggiissaawwaa,, EE .. ((22000033)).. ""SSttuuddyy ooff eeffffeeccttiivveenneessss ooff mmiixxeedd pprroocceesssseedd ffoooodd ccoonnttaaiinniinngg

CC uuccuurrbbiittaa ppeeppoo sseeeedd eexxttrraacctt aanndd ssooyybbeeaann sseeeedd eexxttrraacctt oonn ssttrreessss uurriinnaarryy iinnccoonnttiinneennccee iinn wwoommeenn.."" JJ ppnn Jj MMeedd PP hhaarrmm SS ccii.. 1144((33)):: 331133--332222..

I YY eeggaadd,, MM.. ((22000077)).. KKaabbuukkssuuzz ^''eekkiirrddeekk kkaabbaa//llyy hhaattllaarryyiiddaa ttoohhuumm vveerriimmii vvee kkaalliitteessii,, nn uukkuurroovvaa -- nniivveerrssiitteessii..

i YY eeggaadd,, MM..,, MM.. YΥyγ lΙyγzζ,, HH.. EE lllliiaattllyyoo//lllluu aanndd KK.. AAbbaakk ((22001122)).. ""BBaazzyy KKaabbuukkssuuzz nn eekkiirrddeekk KKaabbaa//llyy ((CC uuccuurrbbiittaa ppeeppoo vvaarr.. ssttyyrriiccaa)) IIssllaahh HHaattllaarryyiiddaa TToohhuumm VVeerriimmii vvee KKaalliitteessii.."" YYYY-- TTAARR BBMM DDEE RR GG 2222((11 )):: 1122--1199..

i ZZeeyybbeekk,, UU.. ((22000066)).. RR eettrriieevveedd 3311..0033..22001144,, 22001144,,

Claims

C LAIMS

1 . T he usage of an herbal formulation comprising pumpkin seed oil, in the production of a medicine used in B P H treatment.

2. A usage as in claim 1 , characterized in that said herbal formulation comprises pumpkin seed oil, dl -tocopherol, di -tocophery! acetate, glycerin, distilled water, and gelatin which provide the integrity of the content and the capsule formation.

3. A usage according to claim 2, characterized in that it is used by adults at a dose of 960 to 2880 mg/day.

4. A usage according to claim 2, characterized in that it is administrated orally.